|Bid||35.90 x 7000|
|Ask||35.91 x 5300|
|Day's Range||35.82 - 36.21|
|52 Week Range||29.83 - 36.21|
|PE Ratio (TTM)||26.28|
|Dividend & Yield||1.28 (3.62%)|
|1y Target Est||N/A|
On September 1, 2017, the FDA approved Pfizer's drug Mylotarg (gemtuzumab ozogamicin) for the treatment of CD33-positive acute myeloid leukemia.
The closely guarded world of drug pricing is getting a public airing in a feud between two of the industry’s biggest companies. The attention drawn to rebates could hurt the profits of some very successful ...
Shares of Pfizer (PFE) have made quite a run in recent weeks. Morgan Stanley’s David Risinger says the drug’s giant’s stock should keep rising, perhaps as high as $44 a share. Earlier today, Risinger upgraded Pfizer from an Equal-weight to an Outperform and set a $39 price target, which is based on a price-to-earnings multiple of 14 times 2018 estimated earnings of $2.76 a share.